Literature DB >> 22449016

Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.

Glaucio Valdameri1, Charlotte Gauthier, Raphaël Terreux, Rémy Kachadourian, Brian J Day, Sheila M B Winnischofer, Maria E M Rocha, Véronique Frachet, Xavier Ronot, Attilio Di Pietro, Ahcène Boumendjel.   

Abstract

ABCG2 plays a major role in anticancer-drug efflux and related tumor multidrug resistance. Potent and selective ABCG2 inhibitors with low cytotoxicity were investigated among a series of 44 chalcones and analogues (1,3-diarylpropenones), by evaluating their inhibitory effect on the transport of mitoxantrone, a known ABCG2 substrate. Six compounds producing complete inhibition with IC(50) values below 0.5 μM and high selectivity for ABCG2 were identified. The number and position of methoxy substituents appeared to be critical for both inhibition and cytotoxicity. The best compounds, with potent inhibition and low toxicity, contained an N-methyl-1-indolyl (compound 38) or a 6'-hydroxyl-2',4'-dimethoxy-1-phenyl (compound 27) moiety (A-ring) and two methoxy groups at positions 2 and 6 of the 3-phenyl moiety (B-ring). Methoxy substitution contributed to inhibition at positions 3 and 5, but had a negative effect at position 4. Finally, methoxy groups at positions 3, 4, and 5 of the B-ring markedly increased cytotoxicity and, therefore, should be avoided.
© 2012 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449016      PMCID: PMC3983950          DOI: 10.1021/jm2016528

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.

Authors:  A van Loevezijn; J D Allen; A H Schinkel; G J Koomen
Journal:  Bioorg Med Chem Lett       Date:  2001-01-08       Impact factor: 2.823

2.  Synthesis and biological activity of 4-alkoxy chalcones: potential hydrophobic modulators of P-glycoprotein-mediated multidrug resistance.

Authors:  F Bois; A Boumendjel; A M Mariotte; G Conseil; A Di Petro
Journal:  Bioorg Med Chem       Date:  1999-12       Impact factor: 3.641

3.  A multidrug resistance transporter from human MCF-7 breast cancer cells.

Authors:  L A Doyle; W Yang; L V Abruzzo; T Krogmann; Y Gao; A K Rishi; D D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

5.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

Authors:  R W Robey; Y Honjo; A van de Laar; K Miyake; J T Regis; T Litman; S E Bates
Journal:  Biochim Biophys Acta       Date:  2001-06-06

6.  Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.

Authors:  Glaucio Valdameri; Luciana Pereira Rangel; Carmela Spatafora; Jérôme Guitton; Charlotte Gauthier; Ophélie Arnaud; Antonio Ferreira-Pereira; Pierre Falson; Sheila M B Winnischofer; Maria E M Rocha; Corrado Tringali; Attilio Di Pietro
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

7.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

8.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

9.  Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance.

Authors:  F Bois; C Beney; A Boumendjel; A M Mariotte; G Conseil; A Di Pietro
Journal:  J Med Chem       Date:  1998-10-08       Impact factor: 7.446

Review 10.  Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.

Authors:  Ahcène Boumendjel; Attilio Di Pietro; Charles Dumontet; Denis Barron
Journal:  Med Res Rev       Date:  2002-09       Impact factor: 12.944

View more
  18 in total

1.  Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.

Authors:  Chung-Pu Wu; Sabrina Lusvarghi; Sung-Han Hsiao; Te-Chun Liu; Yan-Qing Li; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  J Nat Prod       Date:  2020-04-29       Impact factor: 4.050

2.  Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents.

Authors:  Jinyun Dong; Guang Huang; Qijing Zhang; Zengtao Wang; Jiahua Cui; Yan Wu; Qingqing Meng; Shaoshun Li
Journal:  Medchemcomm       Date:  2019-07-02       Impact factor: 3.597

3.  Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.

Authors:  Diana Peña-Solórzano; Matthias Scholler; Günther Bernhardt; Armin Buschauer; Burkhard König; Cristian Ochoa-Puentes
Journal:  ACS Med Chem Lett       Date:  2018-07-25       Impact factor: 4.345

4.  Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity.

Authors:  Carina T Scoparo; Glaucio Valdameri; Paulo R Worfel; Fernanda A L B Guterres; Glaucia R Martinez; Sheila M B Winnischofer; Attilio Di Pietro; Maria E M Rocha
Journal:  Mol Cell Biochem       Date:  2015-07-26       Impact factor: 3.396

5.  Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity.

Authors:  Christopher J Trabbic; Sage M George; Evan M Alexander; Shengnan Du; Jennifer M Offenbacher; Emily J Crissman; Jean H Overmeyer; William A Maltese; Paul W Erhardt
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

6.  ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.

Authors:  Charlotte Gauthier; Csilla Ozvegy-Laczka; Gergely Szakacs; Balazs Sarkadi; Attilio Di Pietro
Journal:  Front Pharmacol       Date:  2013-11-07       Impact factor: 5.810

Review 7.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

8.  Synthesis and biological evaluation of indolyl-pyridinyl-propenones having either methuosis or microtubule disruption activity.

Authors:  Christopher J Trabbic; Jean H Overmeyer; Evan M Alexander; Emily J Crissman; Heather M Kvale; Marcie A Smith; Paul W Erhardt; William A Maltese
Journal:  J Med Chem       Date:  2015-02-19       Impact factor: 7.446

9.  Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position.

Authors:  Evelyn Winter; Gustavo Jabor Gozzi; Louise Domeneghini Chiaradia-Delatorre; Nathalia Daflon-Yunes; Raphael Terreux; Charlotte Gauthier; Alessandra Mascarello; Paulo César Leal; Silvia M Cadena; Rosendo Augusto Yunes; Ricardo José Nunes; Tania Beatriz Creczynski-Pasa; Attilio Di Pietro
Journal:  Drug Des Devel Ther       Date:  2014-05-27       Impact factor: 4.162

10.  New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity.

Authors:  Luciana Pereira Rangel; Evelyn Winter; Charlotte Gauthier; Raphaël Terreux; Louise D Chiaradia-Delatorre; Alessandra Mascarello; Ricardo J Nunes; Rosendo A Yunes; Tania B Creczynski-Pasa; Sira Macalou; Doriane Lorendeau; Hélène Baubichon-Cortay; Antonio Ferreira-Pereira; Attilio Di Pietro
Journal:  Drug Des Devel Ther       Date:  2013-09-30       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.